

KERYX BIOPHARMACEUTICALS INC  
Form 8-K  
May 22, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): May 22, 2014**

**Keryx Biopharmaceuticals, Inc.**

**(Exact Name of Registrant as Specified in Charter)**

**Delaware**  
**(State or Other Jurisdiction**

**of Incorporation)**

**000-30929**  
**(Commission**

**File Number)**  
**750 Lexington Avenue**

**13-4087132**  
**(IRS Employer**

**Identification No.)**

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 8-K

**New York, New York 10022**

**(Address of Principal Executive Offices)**

**(212) 531-5965**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act.
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
- .. Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

**Item 8.01. Other Events.**

On May 22, 2014, Keryx Biopharmaceuticals, Inc. (the Company) issued a press release announcing that the U.S. Food and Drug Administration notified the Company that it has extended the initial Prescription Drug User Fee Act (PDUFA) goal date for its review of the Company's New Drug Application seeking marketing approval of Zerenex<sup>TM</sup> (ferric citrate) by three months. The new PDUFA goal date is September 7, 2014. A copy of the press release is filed as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

The Company hereby filed the following exhibits:

**Exhibit**

<b>Number</b>	<b>Description</b>
99.1	Keryx Biopharmaceuticals, Inc. Press Release dated May 22, 2014.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Keryx Biopharmaceuticals, Inc.**  
(Registrant)

Date: May 22, 2014

By: /s/ James F. Oliviero  
James F. Oliviero, CFA  
Chief Financial Officer

**INDEX TO EXHIBITS**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Keryx Biopharmaceuticals, Inc. Press Release dated May 22, 2014.